Merck & Co. (MRK) : Summit Financial Strategies reduced its stake in Merck & Co. by 6.31% during the most recent quarter end. The investment management company now holds a total of 7,883 shares of Merck & Co. which is valued at $424,736 after selling 531 shares in Merck & Co. , the firm said in a disclosure report filed with the SEC on May 9, 2016.Merck & Co. makes up approximately 0.31% of Summit Financial Strategies’s portfolio.
Other Hedge Funds, Including , Bank Pictet Cie (asia) Ltd reduced its stake in MRK by selling 100 shares or 0.27% in the most recent quarter. The Hedge Fund company now holds 37,412 shares of MRK which is valued at $2,015,759. Merck & Co. makes up approx 1.22% of Bank Pictet Cie (asia) Ltd’s portfolio.Court Place Advisors boosted its stake in MRK in the latest quarter, The investment management firm added 68 additional shares and now holds a total of 25,807 shares of Merck & Co. which is valued at $1,383,255. Merck & Co. makes up approx 0.86% of Court Place Advisors’s portfolio.Hoxton Financial boosted its stake in MRK in the latest quarter, The investment management firm added 100 additional shares and now holds a total of 882 shares of Merck & Co. which is valued at $48,369. Merck & Co. makes up approx 0.02% of Hoxton Financial’s portfolio. Telemus Capital added MRK to its portfolio by purchasing 33,418 company shares during the most recent quarter which is valued at $1,832,643. Merck & Co. makes up approx 0.30% of Telemus Capital’s portfolio.First Midwest Bank Trust Division boosted its stake in MRK in the latest quarter, The investment management firm added 2,876 additional shares and now holds a total of 22,626 shares of Merck & Co. which is valued at $1,240,810. Merck & Co. makes up approx 0.16% of First Midwest Bank Trust Division’s portfolio.
Merck & Co. closed down -0.24 points or -0.44% at $53.88 with 71,25,157 shares getting traded on Friday. Post opening the session at $54.1, the shares hit an intraday low of $53.83 and an intraday high of $54.51 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
On the company’s financial health, Merck & Co. reported $0.89 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on May 5, 2016. Analyst had a consensus of $0.85. The company had revenue of $9312.00 million for the quarter, compared to analysts expectations of $9445.10 million. The company’s revenue was down -1.2 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.85 EPS.
Many Wall Street Analysts have commented on Merck & Co.. Societe Generale Initiated Merck & Co. on Apr 6, 2016 to “Buy”, Price Target of the shares are set at $80.
Merck & Co. Inc. is a global health care company. The Company offers health solutions through its prescription medicines vaccines biologic therapies and animal health products which it markets directly and through its joint ventures. The Companys Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents generally sold by prescription for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers hospitals government agencies and managed health care providers. The Animal Health segment discovers develops manufactures and markets animal health products including vaccines. The Companys animal health products are sold to veterinarians distributors and animal producers.